Glenn Burdette partners up with growth platform for CPA firms
Glenn Burdette has sold to regional accounting and advisory firm Ascend for an undisclosed amount, the San Luis Obispo-based CPA firm announced on June 1. Ascend, backed by private equity firm Alpine Investor, and its platform enables regional accounting firms with between $15 and $50 million of revenue. The company was founded two years ago. Read More →

Procore bolsters operations with two acquisitions

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Sonos delivers earnings win, embraces new era

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
LTC Properties reports first quarter earnings
Westlake Village-based LTC Properties, a real estate investment trust that primarily invests in seniors housing and health care properties, announced operating results for the first quarter ended March 31. LTC generated revenues worth $49 million in the first quarter of 2025, down from $51.3 million in the first quarter of 2024, which the company attributed Read More →
Mission Wealth receives investment from PE firm
Mission Wealth, a Santa Barbara financial planner firm celebrating its 25th year in business, announced it received a minority investment from private equity firm Great Hill Partners. Terms of the transaction were not disclosed. Known for investing in high-growth companies, the partnership will help Mission Wealth’s client service offering and support the firm’s national expansion Read More →
FDA lifts clinical hold on Atara’s lead treatment

Thousand Oaks-based Atara Biotherapeutics received a bit of good news on May 5, after the U.S. Food and Drug Administration announced that it has lifted its hold on Atara’s active Investigational New Drug application for the Ebvallo program. Ebvallo, which is already approved in Europe and is used for transplant-related blood cancer, was placed on Read More →